Developing a Clinico-Molecular Test for Individualized Treatment of Ovarian Cancer: The interplay of Precision Medicine Informatics with Clinical and Health Economics Dimensions

Boris Winterhoff, Stefan Kommoss, Florian Heitz, Gottfried E. Konecny, Sean Christopher Dowdy, Sally A. Mullany, Tjoung Won Park-Simon, Klaus Baumann, Felix Hilpert, Sara Brucker, Andreas du Bois, Willibald Schröder, Alexander Burges, Steven Shen, Jinhua Wang, Roshan Tourani, Sisi Ma, Jacobus Pfisterer, Constantin F. Aliferis

Research output: Contribution to journalArticle

Abstract

We report recent progress in the development of a precision test for individualized use of the VEGF-A targeting drug bevacizumab for treating ovarian cancer. We discuss the discovery model stage (i.e., past feasibility modeling and before conversion to the production test). Main results: (a) Informatics modeling plays a critical role in supporting driving clinical and health economic requirements. (b) The novel computational models support the creation of a precision test with sufficient predictivity to reduce healthcare system costs up to $30 billion over 10 years, and make the use of bevacizumab affordable without loss of length or quality of life.

Original languageEnglish (US)
Pages (from-to)1093-1102
Number of pages10
JournalAMIA ... Annual Symposium proceedings. AMIA Symposium
Volume2018
StatePublished - Jan 1 2018

Fingerprint

Medical Informatics
Precision Medicine
Ovarian Neoplasms
Economics
Informatics
Health
Drug Delivery Systems
Health Care Costs
Vascular Endothelial Growth Factor A
Quality of Life
Delivery of Health Care
Therapeutics
Bevacizumab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Developing a Clinico-Molecular Test for Individualized Treatment of Ovarian Cancer : The interplay of Precision Medicine Informatics with Clinical and Health Economics Dimensions. / Winterhoff, Boris; Kommoss, Stefan; Heitz, Florian; Konecny, Gottfried E.; Dowdy, Sean Christopher; Mullany, Sally A.; Park-Simon, Tjoung Won; Baumann, Klaus; Hilpert, Felix; Brucker, Sara; du Bois, Andreas; Schröder, Willibald; Burges, Alexander; Shen, Steven; Wang, Jinhua; Tourani, Roshan; Ma, Sisi; Pfisterer, Jacobus; Aliferis, Constantin F.

In: AMIA ... Annual Symposium proceedings. AMIA Symposium, Vol. 2018, 01.01.2018, p. 1093-1102.

Research output: Contribution to journalArticle

Winterhoff, B, Kommoss, S, Heitz, F, Konecny, GE, Dowdy, SC, Mullany, SA, Park-Simon, TW, Baumann, K, Hilpert, F, Brucker, S, du Bois, A, Schröder, W, Burges, A, Shen, S, Wang, J, Tourani, R, Ma, S, Pfisterer, J & Aliferis, CF 2018, 'Developing a Clinico-Molecular Test for Individualized Treatment of Ovarian Cancer: The interplay of Precision Medicine Informatics with Clinical and Health Economics Dimensions', AMIA ... Annual Symposium proceedings. AMIA Symposium, vol. 2018, pp. 1093-1102.
Winterhoff, Boris ; Kommoss, Stefan ; Heitz, Florian ; Konecny, Gottfried E. ; Dowdy, Sean Christopher ; Mullany, Sally A. ; Park-Simon, Tjoung Won ; Baumann, Klaus ; Hilpert, Felix ; Brucker, Sara ; du Bois, Andreas ; Schröder, Willibald ; Burges, Alexander ; Shen, Steven ; Wang, Jinhua ; Tourani, Roshan ; Ma, Sisi ; Pfisterer, Jacobus ; Aliferis, Constantin F. / Developing a Clinico-Molecular Test for Individualized Treatment of Ovarian Cancer : The interplay of Precision Medicine Informatics with Clinical and Health Economics Dimensions. In: AMIA ... Annual Symposium proceedings. AMIA Symposium. 2018 ; Vol. 2018. pp. 1093-1102.
@article{46820fb73cec4b9083edabf671be010a,
title = "Developing a Clinico-Molecular Test for Individualized Treatment of Ovarian Cancer: The interplay of Precision Medicine Informatics with Clinical and Health Economics Dimensions",
abstract = "We report recent progress in the development of a precision test for individualized use of the VEGF-A targeting drug bevacizumab for treating ovarian cancer. We discuss the discovery model stage (i.e., past feasibility modeling and before conversion to the production test). Main results: (a) Informatics modeling plays a critical role in supporting driving clinical and health economic requirements. (b) The novel computational models support the creation of a precision test with sufficient predictivity to reduce healthcare system costs up to $30 billion over 10 years, and make the use of bevacizumab affordable without loss of length or quality of life.",
author = "Boris Winterhoff and Stefan Kommoss and Florian Heitz and Konecny, {Gottfried E.} and Dowdy, {Sean Christopher} and Mullany, {Sally A.} and Park-Simon, {Tjoung Won} and Klaus Baumann and Felix Hilpert and Sara Brucker and {du Bois}, Andreas and Willibald Schr{\"o}der and Alexander Burges and Steven Shen and Jinhua Wang and Roshan Tourani and Sisi Ma and Jacobus Pfisterer and Aliferis, {Constantin F.}",
year = "2018",
month = "1",
day = "1",
language = "English (US)",
volume = "2018",
pages = "1093--1102",
journal = "AMIA ... Annual Symposium proceedings / AMIA Symposium. AMIA Symposium",
issn = "1559-4076",
publisher = "American Medical Informatics Association",

}

TY - JOUR

T1 - Developing a Clinico-Molecular Test for Individualized Treatment of Ovarian Cancer

T2 - The interplay of Precision Medicine Informatics with Clinical and Health Economics Dimensions

AU - Winterhoff, Boris

AU - Kommoss, Stefan

AU - Heitz, Florian

AU - Konecny, Gottfried E.

AU - Dowdy, Sean Christopher

AU - Mullany, Sally A.

AU - Park-Simon, Tjoung Won

AU - Baumann, Klaus

AU - Hilpert, Felix

AU - Brucker, Sara

AU - du Bois, Andreas

AU - Schröder, Willibald

AU - Burges, Alexander

AU - Shen, Steven

AU - Wang, Jinhua

AU - Tourani, Roshan

AU - Ma, Sisi

AU - Pfisterer, Jacobus

AU - Aliferis, Constantin F.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - We report recent progress in the development of a precision test for individualized use of the VEGF-A targeting drug bevacizumab for treating ovarian cancer. We discuss the discovery model stage (i.e., past feasibility modeling and before conversion to the production test). Main results: (a) Informatics modeling plays a critical role in supporting driving clinical and health economic requirements. (b) The novel computational models support the creation of a precision test with sufficient predictivity to reduce healthcare system costs up to $30 billion over 10 years, and make the use of bevacizumab affordable without loss of length or quality of life.

AB - We report recent progress in the development of a precision test for individualized use of the VEGF-A targeting drug bevacizumab for treating ovarian cancer. We discuss the discovery model stage (i.e., past feasibility modeling and before conversion to the production test). Main results: (a) Informatics modeling plays a critical role in supporting driving clinical and health economic requirements. (b) The novel computational models support the creation of a precision test with sufficient predictivity to reduce healthcare system costs up to $30 billion over 10 years, and make the use of bevacizumab affordable without loss of length or quality of life.

UR - http://www.scopus.com/inward/record.url?scp=85062378947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062378947&partnerID=8YFLogxK

M3 - Article

C2 - 30815151

AN - SCOPUS:85062378947

VL - 2018

SP - 1093

EP - 1102

JO - AMIA ... Annual Symposium proceedings / AMIA Symposium. AMIA Symposium

JF - AMIA ... Annual Symposium proceedings / AMIA Symposium. AMIA Symposium

SN - 1559-4076

ER -